 Glioblastoma
"Glioblastoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
| Descriptor ID |
D005909
|
| MeSH Number(s) |
C04.557.465.625.600.380.080.335 C04.557.470.670.380.080.335 C04.557.580.625.600.380.080.335
|
| Concept/Terms |
Glioblastoma- Glioblastoma
- Glioblastomas
- Astrocytoma, Grade IV
- Astrocytomas, Grade IV
- Grade IV Astrocytoma
- Grade IV Astrocytomas
Giant Cell Glioblastoma- Giant Cell Glioblastoma
- Giant Cell Glioblastomas
- Glioblastoma, Giant Cell
- Glioblastomas, Giant Cell
|
Below are MeSH descriptors whose meaning is more general than "Glioblastoma".
Below are MeSH descriptors whose meaning is more specific than "Glioblastoma".
This graph shows the total number of publications written about "Glioblastoma" by people in this website by year, and whether "Glioblastoma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1987 | 1 | 0 | 1 | | 1989 | 1 | 0 | 1 | | 1990 | 2 | 0 | 2 | | 1992 | 2 | 0 | 2 | | 1993 | 2 | 0 | 2 | | 1994 | 3 | 3 | 6 | | 1995 | 3 | 0 | 3 | | 1996 | 2 | 0 | 2 | | 1997 | 4 | 0 | 4 | | 1998 | 2 | 0 | 2 | | 1999 | 0 | 1 | 1 | | 2000 | 2 | 0 | 2 | | 2001 | 2 | 1 | 3 | | 2002 | 1 | 2 | 3 | | 2003 | 2 | 0 | 2 | | 2004 | 5 | 0 | 5 | | 2005 | 0 | 1 | 1 | | 2006 | 3 | 2 | 5 | | 2007 | 2 | 3 | 5 | | 2008 | 3 | 0 | 3 | | 2009 | 4 | 2 | 6 | | 2010 | 15 | 1 | 16 | | 2011 | 12 | 0 | 12 | | 2012 | 10 | 0 | 10 | | 2013 | 8 | 5 | 13 | | 2014 | 6 | 3 | 9 | | 2015 | 11 | 1 | 12 | | 2016 | 3 | 0 | 3 | | 2017 | 9 | 0 | 9 | | 2018 | 5 | 2 | 7 | | 2019 | 8 | 0 | 8 | | 2020 | 4 | 0 | 4 | | 2021 | 7 | 0 | 7 | | 2022 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Glioblastoma" by people in Profiles.
-
Xuan W, Hsu WH, Khan F, Dunterman M, Pang L, Wainwright DA, Ahmed AU, Heimberger AB, Lesniak MS, Chen P. Circadian Regulator CLOCK Drives Immunosuppression in Glioblastoma. Cancer Immunol Res. 2022 06 03; 10(6):770-784.
-
Smiley SB, Zarrinmayeh H, Das SK, Pollok KE, Vannier MW, Veronesi MC. Novel therapeutics and drug-delivery approaches in the modulation of glioblastoma stem cell resistance. Ther Deliv. 2022 04; 13(4):249-273.
-
Bi J, Khan A, Tang J, Armando AM, Wu S, Zhang W, Gimple RC, Reed A, Jing H, Koga T, Wong IT, Gu Y, Miki S, Yang H, Prager B, Curtis EJ, Wainwright DA, Furnari FB, Rich JN, Cloughesy TF, Kornblum HI, Quehenberger O, Rzhetsky A, Cravatt BF, Mischel PS. Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug. Cell Rep. 2021 11 02; 37(5):109957.
-
Rahman R, Ventz S, McDunn J, Louv B, Reyes-Rivera I, Polley MC, Merchant F, Abrey LE, Allen JE, Aguilar LK, Aguilar-Cordova E, Arons D, Tanner K, Bagley S, Khasraw M, Cloughesy T, Wen PY, Alexander BM, Trippa L. Leveraging external data in the design and analysis of clinical trials in neuro-oncology. Lancet Oncol. 2021 10; 22(10):e456-e465.
-
Fletcher-Sananikone E, Kanji S, Tomimatsu N, Di Cristofaro LFM, Kollipara RK, Saha D, Floyd JR, Sung P, Hromas R, Burns TC, Kittler R, Habib AA, Mukherjee B, Burma S. Elimination of Radiation-Induced Senescence in the Brain Tumor Microenvironment Attenuates Glioblastoma Recurrence. Cancer Res. 2021 12 01; 81(23):5935-5947.
-
Zhai L, Bell A, Ladomersky E, Lauing KL, Bollu L, Nguyen B, Genet M, Kim M, Chen P, Mi X, Wu JD, Schipma MJ, Wray B, Griffiths J, Unwin RD, Clark SJ, Acharya R, Bao R, Horbinski C, Lukas RV, Schiltz GE, Wainwright DA. Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma. Clin Cancer Res. 2021 12 01; 27(23):6514-6528.
-
Smiley SB, Yun Y, Ayyagari P, Shannon HE, Pollok KE, Vannier MW, Das SK, Veronesi MC. Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma - In Vitro Evaluation in Glioblastoma Stem Cells. Pharm Res. 2021 Jun; 38(6):1067-1079.
-
Chuntova P, Chow F, Watchmaker PB, Galvez M, Heimberger AB, Newell EW, Diaz A, DePinho RA, Li MO, Wherry EJ, Mitchell D, Terabe M, Wainwright DA, Berzofsky JA, Herold-Mende C, Heath JR, Lim M, Margolin KA, Chiocca EA, Kasahara N, Ellingson BM, Brown CE, Chen Y, Fecci PE, Reardon DA, Dunn GP, Liau LM, Costello JF, Wick W, Cloughesy T, Timmer WC, Wen PY, Prins RM, Platten M, Okada H. Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro Oncol. 2021 03 25; 23(3):356-375.
-
Voce DJ, Bernal GM, Cahill KE, Wu L, Mansour N, Crawley CD, Campbell PS, Arina A, Weichselbaum RR, Yamini B. CDK1 is up-regulated by temozolomide in an NF-?B dependent manner in glioblastoma. Sci Rep. 2021 03 11; 11(1):5665.
-
Puduvalli VK, Wu J, Yuan Y, Armstrong TS, Vera E, Wu J, Xu J, Giglio P, Colman H, Walbert T, Raizer J, Groves MD, Tran D, Iwamoto F, Avgeropoulos N, Paleologos N, Fink K, Peereboom D, Chamberlain M, Merrell R, Penas Prado M, Yung WKA, Gilbert MR. A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. Neuro Oncol. 2020 10 14; 22(10):1505-1515.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|